IL6 and breast carcinoma: In breast cancer, it has also been observed that interlukin -6 (IL-6), secreted by breast cancer-associated MSCs, protected cancer cells from cisplatin-induced apoptosis by activating the signal transducer and activator of the transcription 3 (STAT3) pathway [15].